April 2013 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the April 2013 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

New listings

- Glyceryl trinitrate (Rectogestic) oint 0.2%, 30 g OP – Special Authority – Retail pharmacy (p’code 2120313)
- Diazoxide (Proglicem) cap 25 mg (2434628) and 100 mg (p’code 2434601) – Special Authority – Retail pharmacy – S29
- Bismuth trioxide (De-Nol) tab 120 mg – S29 (p’code 2434679)
- Propranolol (Roxane) oral liq 4 mg per ml – Special Authority – Retail pharmacy (p’code 2401894) – S29
- Metolazone (Metolazone) tab 5 mg – Special Authority – Retail pharmacy – (p’code 2436108)
- Hydralazine hydrochloride (Hydralazine) tab 25 mg – Special Authority – Retail pharmacy – (p’code 2436116)
- Albendazole (Eskazole) tab 400 mg – Special Authority – Retail pharmacy – S29 (p’code 2429977)
- Praziquantel (Biltricide) tab 600 mg (p’code 2028808)
- Paromomycin (Humatin) cap 250 mg – Special Authority – Retail pharmacy – S29 (p’code 2434652)
- Tetracycline (Tetacyclin Wolff) cap 500 mg – Special Authority – Retail pharmacy – S29 (p’code 2434660)
- Pyrimethamine (Daraprim) tab 25 mg – Special Authority – Retail pharmacy – S29 (p’code 2086883)
- Sulfadiazine sodium (Wockhardt) tab 500 mg – Special Authority – Retail pharmacy – S29 (p’code 2034441)
- Itraconazole (Sporanox) oral liq 10 mg per ml, 150 ml OP – Special Authority-Retail pharmacy (p’code 485411)
- Para-amino salicylic acid (Paser) grans for oral liq 4 g sachet – Retail pharmacy-Specialist – S29 – no patient co-payment payable (p’code 2254921)
- Protionamide (Peteha) tab 250 mg – no patient co-payment payable – no patient co-payment payable – Retail pharmacy-Specialist – S29 – no patient co-payment payable (p’code 2434695)
- Cycloserine (King) cap 250 mg – Retail pharmacy-Specialist – S29 – no patient co-payment payable (p’code 2354179)
- Clofazimine (Lamprene) cap 50 mg – Retail pharmacy-Specialist – S29 – no patient co-payment payable (p’code 654450)
- Primaquine phosphate (Primacin) tab 7.5 mg – Special Authority – Retail pharmacy (p’code 2435985) – S29
- Efavirenz (Stocrin) oral liq 30 mg per ml, 180 ml OP – Special Authority – Retail pharmacy – S29 (p’code 2436337)
- Stavudine [D4T] (Zerit) powder for oral soln 1 mg per ml, 200 ml OP – Special Authority – Retail pharmacy – S29 (p’code 429414)
- Benzbromarone (Benzbromaron) tab 100 mg – Special Authority – Retail pharmacy – S29 (p’code 2434598)
- Selegiline hydrochloride (Apo-Selegiline S29) tab 5 mg – S29 (p’code 2374420)
- Stiripentol (Diacomit) cap 250 mg (p’code 2434636) and powder for oral liq 250 mg sachet (p’code 2434644) – Special Authority – Retail pharmacy – S29
• Pegaspargase (Oncaspar) inj 3,750 IU per 5 ml – PCT only – Specialist – Special Authority (p’code 2086190)
• Docetaxel (Docetaxel Sandoz) inj 20 mg (p’code 2428148) and 80 mg (p’code 248156) – PCT only – Specialist
• Olopatadine (Patanol) eye drops 0.1%, 5 ml OP (p’code 2099365)
• Pharmacy Services (BSF Nevirapine Alphapharm) - Brand switch fee (p’code 2433265)
• High fat low carbohydrate formula (Ketocal 3:1) powder (unflavoured), 300 g OP (p’code 2431637)

Changes to restrictions
• Felodipine (Plendil ER) tab long-acting 5 mg and 10 mg – removal of brand switch fee payable
• Ciprofloxacin (Cipflox) tab 250 mg, 500 mg and 750 mg – change to restriction
• Clindamycin (Clindamycin ABM) cap hydrochloride 150 mg and (Dalacin C) inj phosphate 150 mg per ml, 4 ml – Specialist type added to Retail pharmacy-Specialist
• Fusidic acid (Fucidin) tab 250 mg – Specialist type added to Retail pharmacy-Specialist
• Lincomycin (Lincocin) inj 300 mg per ml, 2 ml – Specialist type added to Retail pharmacy-Specialist
• Itraconazole (Itrazole) cap 100 mg - Subsidy by endorsement
• Ketoconazole (Nizoral) tab 200 mg – Specialist type added to Retail pharmacy-Specialist
• Dapsone (Dapsone) tab 25 mg and 100 mg– Specialist type added to Retail pharmacy-Specialist
• Ethambutol hydrochloride (Myambutol) tab 100 g and 400 mg – Specialist type added to Retail pharmacy-Specialist
• Isoniazid (PSM) tab 100 mg, (Rifinah) tab 100 mg with rifampicin 150 mg and tab 150 mg with rifampicin 300 mg – Specialist type added to Retail pharmacy-Specialist
• Pyrazinamide (AFT-Pyrazinamide) tab 500 mg – Specialist type added to Retail pharmacy-Specialist
• Rifabutin (Mycobutin) cap 150 mg – Specialist type added to Retail pharmacy-Specialist
• Rifampicin (Rifadin) tab 600 mg, cap 150 mg, cap 300 mg, oral liq 100 mg per 5 ml – Specialist type added to Retail pharmacy-Specialist
• Nevirapine (Nevirapine Alphapharm) addition of brand switch fee payable
• Interferon alpha-2a (Roferon-A) inj 3 m iu, 6 m iu and 9 m iu prefilled syringe – Specialist type added to Retail pharmacy - Specialist
• Interferon alpha-2b (Intron-A) inj 18 m iu, 1.2 multidose pen, inj 30 m iu, 1.2 multidose pen, inj 60 m iu, 1.2 multidose pen - Specialist type added to Retail pharmacy-Specialist
• Oral feed 1.5 kcal/ml, oral feed with fibre 1.5 kcal/ml and oral feed 2kcal/ml – change to additional subsidy by endorsement
• KetoCal brand name changed to KetoCal 4:1

Increased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxybutynin</td>
<td>Oral liq 5 mg per 5 ml</td>
<td>Apo-Oxybutynin</td>
</tr>
</tbody>
</table>

Decreased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidized brands</th>
<th>Partially subsidized brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinapril</td>
<td>Tab 5 mg</td>
<td>Arrow-Quinapril 5*</td>
<td>Accupril</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg</td>
<td>Arrow-Quinapril 10*</td>
<td>Accupril</td>
</tr>
<tr>
<td></td>
<td>Tab 20 mg</td>
<td>Arrow-Quinapril 20*</td>
<td>Accupril</td>
</tr>
<tr>
<td>Oxybutynin</td>
<td>Tab 5 mg</td>
<td>Apo-Oxybutynin</td>
<td></td>
</tr>
<tr>
<td>Baclofen</td>
<td>Tab 10 mg</td>
<td>Pacifen</td>
<td></td>
</tr>
<tr>
<td>Norlortriptyline</td>
<td>Tab 10 mg and 25 mg</td>
<td>Norpress</td>
<td></td>
</tr>
</tbody>
</table>

* no subsidy changes for these brands
Wastage Rule extended to Section 29 medicines

From 1 April 2013, Rule 3.3.2 that currently applies to specified oral liquid antibiotics will now also apply to all funded medicines supplied under section 29 of the Medicines Act 1981. These are indicated by the S29 symbol in the Pharmaceutical Schedule.

This rule allows pharmacists to claim the remainder of partly-dispensed packs if the remaining stock is not able to be dispensed. If a patient has repeats, the wastage should only be claimed once the prescription is completed. If a patient returns with a new prescription and the pharmacist has not discarded the stock, the pharmacy should unclaim the wastage and continue to use stock.

The wastage rule is different from the Original Pack rule where the entirety of the pack must be claimed at each dispensing. We note that it is considered fraud to claim wastage and then use the remaining product.

Please contact PHARMAC at 0800 66 00 50 if you have any questions regarding this rule change.